Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer

D. S. Ettinger; S. E. Order; M. D. Wharam; M. K. Parker; J. L. Klein; P. K. Leichner

Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer

D. S. Ettinger, S. E. Order, M. D. Wharam, M. K. Parker, J. L. Klein, P. K. Leichner

School of Medicine

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

A phase I-II study of isotopic immunoglobulin therapy was performed in 18 patients with primary liver cancer; 14 were evaluable for toxicity. The patients received a dose of 37-157 millicuries of ¹³¹I-labeled antibody. The dose-limiting factor appears to be hematologic toxicity, especially thrombocytopenia. An objective antitumor effect was seen in six of nine patients who were evaluable for response. Present results suggest that further clinical studies with isotopic immunoglobulin are indicated.

Original language	English (US)
Pages (from-to)	289-297
Number of pages	9
Journal	Cancer treatment reports
Volume	66
Issue number	2
State	Published - 1982

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{687103045fc54a5e94ee62394104c1cf,

title = "Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer",

abstract = "A phase I-II study of isotopic immunoglobulin therapy was performed in 18 patients with primary liver cancer; 14 were evaluable for toxicity. The patients received a dose of 37-157 millicuries of 131I-labeled antibody. The dose-limiting factor appears to be hematologic toxicity, especially thrombocytopenia. An objective antitumor effect was seen in six of nine patients who were evaluable for response. Present results suggest that further clinical studies with isotopic immunoglobulin are indicated.",

author = "Ettinger, {D. S.} and Order, {S. E.} and Wharam, {M. D.} and Parker, {M. K.} and Klein, {J. L.} and Leichner, {P. K.}",

year = "1982",

language = "English (US)",

volume = "66",

pages = "289--297",

journal = "Cancer treatment reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer

AU - Ettinger, D. S.

AU - Order, S. E.

AU - Wharam, M. D.

AU - Parker, M. K.

AU - Klein, J. L.

AU - Leichner, P. K.

PY - 1982

Y1 - 1982

N2 - A phase I-II study of isotopic immunoglobulin therapy was performed in 18 patients with primary liver cancer; 14 were evaluable for toxicity. The patients received a dose of 37-157 millicuries of 131I-labeled antibody. The dose-limiting factor appears to be hematologic toxicity, especially thrombocytopenia. An objective antitumor effect was seen in six of nine patients who were evaluable for response. Present results suggest that further clinical studies with isotopic immunoglobulin are indicated.

AB - A phase I-II study of isotopic immunoglobulin therapy was performed in 18 patients with primary liver cancer; 14 were evaluable for toxicity. The patients received a dose of 37-157 millicuries of 131I-labeled antibody. The dose-limiting factor appears to be hematologic toxicity, especially thrombocytopenia. An objective antitumor effect was seen in six of nine patients who were evaluable for response. Present results suggest that further clinical studies with isotopic immunoglobulin are indicated.

UR - http://www.scopus.com/inward/record.url?scp=0020032912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020032912&partnerID=8YFLogxK

M3 - Article

C2 - 6275989

AN - SCOPUS:0020032912

SN - 0361-5960

VL - 66

SP - 289

EP - 297

JO - Cancer treatment reports

JF - Cancer treatment reports

IS - 2

ER -

Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this